Overall rank by patents
#3,274
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
USPTO PatentsView assignee record — 114 granted patents across 15 technology areas, active 2017–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
114
Total patents granted
15
CPC technology areas
16.8
Avg claims per patent
+256%
5-year filing velocity
The verdict
Chia holds 114 US patents across 15 technology areas — rank #3,274 of 50,000 tracked assignees.
- #3,274
- of 50,000 US assignees by volume
- Top 25%
- by Innovation Score (44.6/100)
- 16.8
- avg claims per patent
- +256%
- filing velocity, last 5 yrs
Portfolio overview
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. has been granted 114 US utility patents between 2017 and 2025, placing Chia Tai Tianqing Pharmaceutical Group Co., Ltd. at rank #3,274 across all assignees tracked by PlainPatent. This portfolio spans 15 distinct Cooperative Patent Classification (CPC) subclasses, averaging 16.8 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 44.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 89 grants, compared with 25 in the 2015–2019 window — a +256% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s 16.8 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 15 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Chia Tai Tianqing Pharmaceutical Group Co., Ltd. against peers pursuing similar technology classes.
How does Chia compare?
Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀
- Samsung
SAMSUNG ELECTRONICS CO., LTD.
106,890 patents
- International Bus…
International Business Machines Corporation
72,926 patents
- Canon 34,378
Canon Kabushiki Kaisha
34,378 patents
- LG 32,607
LG ELECTRONICS INC.
32,607 patents
- Taiwan Semiconduc… 31,041
TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY LTD.
31,041 patents
- Apple 30,560
Apple Inc.
30,560 patents
- Qualcomm Incorpor… 30,354
QUALCOMM Incorporated
30,354 patents
- Intel 27,498
Intel Corporation
27,498 patents
- Chia Tai Tianqing… ◀ 114
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
114 patents
What this shows Chia holds 114 patents — placing it at rank #3,274 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.
Chia's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
45 Top 25% higher than 75% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView — PlainPatent Innovation Score · 2015–2025
USPTO utility patent grants by year · 2017–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2017 | 4 | 3.5% |
| 2018 | 10 | 8.8% |
| 2019 | 11 | 9.6% |
| 2020 | 24 | 21.1% |
| 2021 | 14 | 12.3% |
| 2022 | 14 | 12.3% |
| 2023 | 7 | 6.1% |
| 2024 | 12 | 10.5% |
| 2025 | 18 | 15.8% |
Which technologies does Chia Tai Tianqing Pharmaceutical Group Co., Ltd. patent most?
Top 15 of 15 technology areas
Patent Moat Analysis
Portfolio Volume Moderate
Tech Breadth Focused
Claim Depth Standard
Velocity Accelerating
Frequently Asked Questions
How many patents does Chia Tai Tianqing Pharmaceutical Group Co., Ltd. hold?
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. holds 114 US granted patents filed between 2017 and 2025, spanning 15 technology areas.
What is Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s Innovation Score?
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. has an Innovation Score of 44.6 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Chia Tai Tianqing Pharmaceutical Group Co., Ltd. focus on?
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 100 patents. The company has filed patents in 15 CPC subclasses total.
Is Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s patent filing rate increasing or decreasing?
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s recent filing velocity is +256% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s patents?
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s patents average 16.8 claims each. This falls within the standard range, providing solid legal coverage.
How is the Chia Tai Tianqing Pharmaceutical Group Co., Ltd. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
Learn More
Explore the patent dataset
A61P technology
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s primary CPC class — all holders and yearly trends
Top 50 patent holders
See where Chia Tai Tianqing Pharmaceutical Group Co., Ltd. ranks among the largest US patent assignees
All technology classes
Browse every CPC technology area by patent activity
How the score works
The four dimensions behind the Innovation Score
Related
Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
All federal data sources used on this page
- USPTO PatentsView — official U.S. Patent and Trademark Office bulk patent data. patentsview.org
- USPTO Patent Application Information Retrieval (PAIR) — application status and file history. uspto.gov/patents/pair
- USPTO Bulk Data Storage System — comprehensive patent text + claims dataset. bulkdata.uspto.gov
- USPTO CPC Classification — Cooperative Patent Classification scheme for technology categorization. uspto.gov/cpc
- SEC EDGAR — public filings cross-reference for assignee corporate entity matching. sec.gov/edgar
- WIPO PATENTSCOPE — international patent context (related international filings). wipo.int/patentscope
